<DOC>
	<DOCNO>NCT02158052</DOCNO>
	<brief_summary>This pilot trial offer unique opportunity treatment multiple myeloma systemic AL amyloidosis hematopoietic stem cell transplantation would ordinarily indicate reversal end-stage renal failure , avoid risk associate long-term standard anti-rejection therapy use renal transplantation . The primary objective study assess renal allograft tolerance ( , acceptance kidney without need anti-rejection therapy ) , assess anti-tumor response rate multiple myeloma AL amyloidosis , assess complication rate genetically ( HLA ) match related donor combine bone marrow kidney transplantation use low dose total body irradiation base preparative regimen .</brief_summary>
	<brief_title>Combined Bone Marrow Renal Transplantation Hematologic Disorders With End Stage Renal Disease</brief_title>
	<detailed_description>The induction transplantation tolerance involve specific elimination immune response transplant antigen . In realm kidney transplantation , tolerance mean recipient unable detect donor transplant kidney foreign , therefore recipient unable reject kidney . Donor bone marrow engraftment lead kidney graft tolerance animal model . Renal failure major complication multiple myeloma AL amyloidosis know cure allogeneic bone marrow transplantation . Standard bone marrow transplantation associate prohibitive toxicity patient end stage renal disease , generally consider option patient . Patients multiple myeloma AL amyloidosis exclude conventional renal transplantation protocol underlying malignancy . A less toxic bone marrow transplantation protocol , utilize low dose total body irradiation anti-thymocyte globulin , combine renal transplantation , could provide opportunity cure myeloma amyloidosis correction end stage renal disease . In addition , successful marrow engraftment may expect lead state tolerance . Successful implementation tolerance would major benefit transplant recipient . The significance develop tolerance patient could spar disable complication indefinite immunosuppression , include infection , cataract , osteoporosis , diabetes , atherosclerosis , hypertension , malignancy .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Pancytopenia</mesh_term>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>Participant Inclusion Criteria Participants endstage renal failure due association multiple myeloma systemic AL amyloidosis hematopoietic cell transplantation appropriate â‰¥ 50 % fiveyear survival probability transplantation expect . This include , limited : Multiple myeloma ( MM ) , ISS stage II III complete good partial remission AL amyloidosis without significant cardiac disease Males females 18 65 year age . Participants must HLAmatched one six HLA A , B , DR antigenmismatched related donor , high resolution molecular class I II allele type . Men woman reproductive potential must agree use reliable method birth control treatment , woman period 2 year follow transplant . Participants dialysis CrCl &lt; 20 ml/min . Patients evidence renal recovery renal failure 90 day period therapy underlying malignancy blood disorder . Patients history malignancy exclude basal cell carcinoma skin carcinoma situ cervix diseasefree survival interval &gt; 2 year . Patients follow malignancy must demonstrate 5 year diseasefree survival : Breast cancer positive node Malignant melanoma ( situ ) Colorectal cancer ( Dukes Stage A B1 ) Patients multiple myeloma must receive previous treatment bortezomibbased regimen . Patients AL amyloidosis must receive previous treatment bortezomibbased regimen and/or autologous stem cell transplantation Patients history malignant melanoma must review independent oncologist prior enrollment . Recipient ability understand provide inform consent . Participant Exclusion Criteria Evidence active infection define : ) clinical syndrome consistent viral bacterial infection ( e.g. , influenza , URI , UTI ) b ) fever clinical site infection identify , c ) microbiologically document infection , include , limited , bacteremia septicemia . Participation investigational drug use time enrollment . Contraindication therapy one propose agent ( e.g. , history allergy horse serum ATG ) . Serologic positivity HIV HCV . Women childbearing age adequate contraception maintain . AST/ALT &gt; 3 x normal bilirubin &gt; 1.5 x normal ( unless due Gilbert 's syndrome ) . Pregnancy uncontrolled serious medical illness relate underlying myeloma . Cardiac ejection fraction &lt; 40 % echocardiogram . FEV1 &lt; 50 % predict correct DLCO &lt; 50 % predict . ABO blood group incompatibility hostvsgraft direction . Diagnosis myelodysplastic syndrome Donor Inclusion Criteria HLAmatched one six HLA A , B , DR antigenmismatched related male female donor 1865 year age . ECOG performance status 0 1 . Excellent health per conventional predonor history ( medical psychosocial evaluation ) . Acceptable laboratory parameter ( hematology normal nearnormal range ; liver function &lt; 2 time upper limit normal normal creatinine ) . Compatible ABO blood group . Negative donor lymphocyte crossmatch . No positive test viral infection ( HbsAg , HIV , HCV , HTLV1 ) . Cardiac/Pulmonary evaluation within normal limit ( CXR , EKG ) . Donor ability understand provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HLA match</keyword>
	<keyword>bone marrow transplantation</keyword>
	<keyword>kidney transplantation</keyword>
</DOC>